Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article
Arrival of the 5G Era of Clinical Medicine for Breast Cancer

Nan Zhang, Xiangying Xin, Deqiao Wu, Yan Zhang*, Hui Chen, Nannan Feng, Junwei Zhang, Yifan Zhu, Zhenzhong Zhang and Xia Xu

School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China

*Corresponding Author: Yan Zhang, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.

Received: December 23, 2020; Published: January 16, 2021

×

Abstract

  Breast cancer is one of the most common malignant tumors among women worldwide. Since the 1970s, the incidence of breast cancer has always been the highest in women with tumors. Its incidence has shown an upward trend. Clinical medication for breast cancer has also been updated owing to social progress and development, particularly in the current mobile data networks. The mobile data network evolved from the 1G to the 5G era. Upon consulting literature, combined with the current understanding of the clinical application of breast cancer, the developmental changes and prospects of the clinical application of breast cancer in the 5G era were summarized. This review focused on the development of breast cancer from the 1G to 5G era. Beginning from the advent of the era of efficacy of the 1G era, represented by the introduction of paclitaxel and doxorubicin, to changes in docetaxel and epirubicin, with the arrival of the transitional era represented by chemical structure. With the advancement of science and technology, we entered the targeted era, represented by nano-preparations such as albumin paclitaxel and liposomal adriamycin. Currently, we are utilizing multi-drug combination therapy.

Keywords: Breast Cancer; Clinical Medication; 5G Era

×

References

  1. Thani I and T Kasbe. “Breast Cancer: State -of- the-art causes and diagnosis”. in 2nd International Conference on Data, Engineering and Applications (IDEA) (2020).
  2. Fang J., et al. “Clinical Analysis of 67 Cases of Mastitis in Non-lactating Period”. China Health Standard Management (2017).
  3. Tavani A., et al. “Attributable risks for breast cancer in Italy: Education, family history and reproductive and hormonal factors”. International Journal of Cancer2 (2015): 159-163.
  4. Anderson JAD. “Occupation as a modifying factor in the diagnosis and treatment of rheumatic diseases”. Current Medical Research and Opinion9 (1974): 521-528.
  5. Yang J., et al. “The Relationship between Level of Estrogen in Postmenopausal Metastatic Breast Cancer and the Efficacy of Fulvestrant”. Pharmaceutical Journal of Chinese Peoples Liberation Army (2016).
  6. , et al. “Cigarette smoking and the risk of breast cancer”. American Journal of Epidemiology 131.2 (2016): 244-253.
  7. Lidija RM and R Sinia. “Breast cancer susceptibility Gene 2 - BRCA2”. Archive of Oncology2 (2001): 115-118.
  8. Turner N., et al. “Continued value of adjuvant anthracyclines as treatment for early breast cancer”. Lancet Oncology7 (2015): e362-e369.
  9. , et al. “New developments in antitumor anthracyclines”. Pharmacology and Therapeutics (1997).
  10. Dezhenkova LG., et al. “Topoisomerase I and II inhibitors: Chemical structure, mechanisms of action and role in cancer chemotherapy”. Russian Chemical Reviews1 (2014): 82.
  11. Berthiaume JM and KB Wallace. “Persistent Alterations to the Gene Expression Profile of the Heart Subsequent to Chronic Doxorubicin Treatment”. Cardiovascular Toxicology3 (2007): 178-191.
  12. Rodman MJ. “FDA approvals: '92 in review”. RN 56.3 (1993): 50-54.
  13. Б СM., et al. “Таксол в сочетании с доксорубицином при лечении больных диссеминированным раком молочной железы”. Вестникронцим.н.н:блохинарамн (1997).
  14. Bouzada AO., et al. “Pharmaceutical formulation comprising taxane, a solid composition of taxane, a process for preparing said solid composition of taxane, a solubilizing composition of said solid composition of taxane, and a kit for the injectable formulation of taxane”. US (2009).
  15. Sparreboom A., et al. “Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications”. Cancer Research7 (1999): 1454-1457.
  16. Kirikae T., et al. “Structural significance of the benzoyl group at the C-3'-N position of paclitaxel for nitric oxide and tumor necrosis factor production by murine macrophages”. Biochemical and Biophysical Research Communications 3 (1998): 698-704.
  17. Plosker GL and D Faulds. “Epirubicin. A review of its pharmacodynamic and harmacokinetic properties, and therapeutic use in cancer chemotherapy”. Drugs5 (1993): 788-856.
  18. Gradishar and J William. “Albumin-bound paclitaxel: a next-generation taxane”. Expert Opinion on Pharmacotherapy 8 (2016): 1041.
  19. Meng S., et al. “Integrin-targeted paclitaxel nanoliposomes for tumor therapy”. Medical Oncology4 (2011): 1180-1187.
  20. Oerlemans, C., et al. “Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release”. Pharmaceutical Research12 (2010): 2569-2589
  21. Schuyler D. “Metastatic Breast Cancer: Albumin-Bound Paclitaxel Found More Effective, Less Toxic than Standard Paclitaxel”. Oncology Times11 (2005): 1166-1177.
  22. Nyman and W D. “Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies”. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology31 (2005): 7785-7793.
  23. Dhanikula AB., et al. “Pharmacokinetic study of paclitaxel as a 3-hour infusion in anIndian population: 135 mg/m2 vs. 175 mg/m2”. Methods and Findings in Experimental and Clinical Pharmacology 2 (2001): 93-98.
  24. Kawamura, M., et al. “Administration of low-dose albumin-bound Paclitaxel for thetreatment of advanced and recurrent breast cancer patients”. Gan to Kagaku Ryoho Cancer and Chemotherapy7 (2013): 909-912.
  25. , et al. “Enzyme entrapment in liposomes”. Febs Letters (1971).
  26. Liu D., et al. “Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes”. Biochimica Et Biophysica Acta1 (1992): 95.
  27. , et al. “Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin”. Journal of Controlled Release Official Journal of the Controlled Release Society 232 (2016): 255-264.
  28. Zhang, Y., et al. “Construction and antitumor effects of antitumor micelles with cyclic RGD-modified anlotinib”. Nanomedicine 28 (2020): 102224.
  29. Gucalp, A and TA Traina. “Androgen receptor‐positive, triple‐negative breast cancer”. Cancer 10 (2017).
  30. , et al. “Letrozole”. American Journal of Cancer (2002).
  31. Smedira HJ. “Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate”. Archives of Internal Medicine20 (2000): 3034-3042.
  32. Yongzhen H., et al. “Effect of endogenous glucocorticoid on expression of p53 and Bcl-2 proteins in osteocyte apoptosis in avascular necrosis of the femoral head induced by alcoholism”. Guizhou Medical Journal (2004).
  33. Wiseman LR and KL Goa Formestane. “A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer”. Drugs Aging4 (1996): 292-306.
  34. Mouridsen H., et al. “Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer”. Breast Diseases A Year Book Quarterly 2 (2009): 168-169.
  35. Carraway H and AC Wolff. “Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer”. Cancer Treatment Reviews3 (2004): 303-307.
  36. Goss PE., et al. “Exemestane for Breast-Cancer Prevention in Postmenopausal Women”. New England Journal of Medicine25 (2011): 2381-2391.
  37. a, D.A.M.C.M., et al. “Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial” (2012).
  38. Gampe RT., et al. “Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix”. Genes and Development17 (2000): 2229.
  39. Stenbygaard LE., et al. “Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial”. Breast Cancer Research and Treatment1 (1993): 57-63.
  40. Walsh and W Brian. “Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women”. Jama18 (1998): 1445-1451.
  41. , et al. “Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma”. Cancer 104.2 (2005).
  42. István P. “Role of gonadotropin-releasing hormone (GnRH, LH-RH) analogues in the therapy of cancer”. Magyar Onkológia1 (1999): 19-24.
  43. Navarro MA., et al. “[The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer]”. Medicina Clní ica18 (1995): 681.
  44. Lei F., et al. “Targeted therapy in breast cancer: what's new?” Swiss Medical Weekly141 (2011): w13231.
  45. Andre F., et al. “Everolimus, Paclitaxel, Trastuzumab, Breast Cancer”. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology34 (2010): 5110-5115.
  46. Portera CC., et al. “Cardiotoxicity of trastuzumab, Cardiac toxicity, pertuzumab, breast cancer”. Clinical Cancer Research An Official Journal of the American Association for Cancer Research9 (2008): 2710.
  47. , et al. “HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer”. International Journal of Molecular Sciences 20.5 (2019): 1115.
  48. Bilancia D., et al. “Lapatinib, breast cancer”. Annals of Oncology 6 (2007): vi26-30.
  49. Burstein HJ., et al. “VEGF, Breast Cancer, Bevacizumab, Vinorelbine, Marker”. Clinical Cancer Research An Official Journal of the American Association for Cancer Research23 (2008): 7871-7877.
  50. Juranic Z., et al. “The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab – Herceptin”. Archive of Oncology3 (2002): 162-163.
  51. Release FN. “FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment”. Molecular and Cellular Pharmacology (2013).
  52. Reports, F.S. “FDA begins process to remove breast cancer indication from Avastin label” (2010).
  53. Li D., et al. “Tumor associated macrophages secrete CCL2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer”. Cancer Science 1 (2019).
  54. Awada, A., et al. “mTOR, RAD001, everolimus, breast cancer”. European Journal of Cancer1 (2008): 84-91.
  55. Hu Y., et al. “Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells”. Cell Death and Disease12 (2015): e2020.
  56. Salazar R., et al. “BRCA1-2 mutations in breast cancer: Identification of nine new variants of BRCA1-2 genes in a population from central Western Spain”. Cancer Letters1 (2006): 172-177.
  57. Seelbach-Gobel., et al. “Berlin, 22nd May 2017 252nd Opinion of the DGGG: Opinion on Palbociclib (Breast Cancer)”. Geburtshilfe Und Frauenheilkunde (2017).
  58. Hortobagyi GN., et al. “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer”. The New England Journal of Medicine 18 (2016): 1738-1748.
  59. Alajez NM. “Abstract 301: Concurrent targeting of BMI1 and CDK4/6 inhibited breast cancer tumorigenicity in vitro and in vivo”. in Proceedings: AACR Annual Meeting 2019 March 29-April 3, 2019 Atlanta, GA (2019).
  60. Konno R. “HPV (human papillomavirus) vaccine”. Nihon Rinsho7 (2012): 175-183.
  61. Bella SD., et al. “Altered maturation of peripheral blood dendritic cells in patients with breast cancer”. British Journal of Cancer8 (2003): 1463.
  62. , et al. “Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker”. International Journal of Gynecological Cancer Official Journal of the International Gynecological Cancer Society 12.1 (2002): 74-79.
  63. “RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM (E75) and Trastuzumab Breast Cancer at ASCO”. Biomedical Market Newsletter (2011).
×

Citation

Citation: Yan Zhang., et al. “Arrival of the 5G Era of Clinical Medicine for Breast Cancer”. Acta Scientific Pharmaceutical Sciences 5.2 (2021): 17-26.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 10, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US